INO-9012

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

46 competitors in Pembrolizumab

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

1352

Stivarga

Bayer

Phase 3

33

Lenvima

Eisai

Phase 2

114

Taxol

Teva

Phase 2

75

Paraplatin

AAvyxa

Phase 2

126

Lynparza

AstraZeneca

Phase 2

27

Cyramza

Eli Lilly

Phase 2

28

Trodelvy

Gilead

Phase 2

29

Alimta

SShawn Eagle

Phase 2

710

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

5Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

HCC2 trials

An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma

Active, not recruiting·GGeneos Therapeutics·Preclinical·NCT04251117·36 enrolled

IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Recruiting·GGeneos Therapeutics·Phase 2·NCT07722741·90 enrolled

Immunotherapy1 trial

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Completed·Inovio Pharmaceuticals·Phase 1·NCT02960594·93 enrolled

Vaccination1 trial

Therapeutic Vaccination in Treated HIV Disease

Completed·SSteven Deeks·Phase 1/2·NCT03606213·56 enrolled

Glioblastoma1 trial

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

Active, not recruiting·Inovio Pharmaceuticals·Preclinical·NCT03491683·52 enrolled

BRCA1/2 Mutation1 trial

Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations

Active, not recruiting·AAbramson Cancer Center at Penn Medicine·Phase 1·NCT04367675·44 enrolled

1 more indication

Urothelial Carcinoma1 trial

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Completed·Inovio Pharmaceuticals·Preclinical·NCT03502785·35 enrolled

Details

Drug Info

Related News